GLI1 and breast cancer: Gli1 positivity in both breast cancer (n = 4, OR: 2.10, 95% CI: [1.54, 2.86], P < 0.00001, I2 = 0%) and ovarian cancer (n = 3, OR: 6.28, 95% CI: [1.07, 36.69], P = 0.04, I2 = 38%) acted as an indicator of a worse 10-year overall survival, while its over-expression in medulloblastoma (n = 3, OR: 1.60, 95% CI: [0.25, 10.40], P = 0.62, I2 = 86%) was unable to offer a prognostic prediction as above (Supplementary Figure S15).